[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pad":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,68,95,123,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642091","home-based-lower-extremity-heat-therapy-for-walking-function-in-peripheral-artery-disease-100642091",false,"NCT07653243","Home-Based Lower-Extremity Heat Therapy for Walking Function in Peripheral Artery Disease","A Randomized, Sham-Controlled Trial of Home-Based Lower-Extremity Heat Therapy in Adults With Peripheral Artery Disease","Inclusion Criteria:\n\n* Men and women older than 50 years of age\n* Resting ankle-brachial index (ABI) of \\\u003C0.9 but \\>0.4 in at least one leg\n\nExclusion Criteria:\n\n* Critical limb ischemia (ischemic rest pain or ischemia-related, non-healing wounds or tissue loss\n* Prior amputation\n* Exercise-limiting comorbidity\n* Recent (\\\u003C3 months) lower-extremity revascularization or orthopedic surgery\n* Use of walking aid other than a cane\n* Active treatment for cancer\n* Chronic kidney disease (eGFR \\\u003C30 by MDRD or Mayo or Cockcroft-Gault formula)\n* Class 2 or 3 obesity (BMI ≥ 35 kg\u002Fm2)\n* Unable to fit into water-circulating trousers","ALL","50 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","Lower-extremity peripheral artery disease is associated with impaired walking ability, reduced lower-extremity function, and decreased quality of life. This randomized, sham-controlled clinical trial will evaluate the effects of 12 weeks of home-based lower-extremity heat therapy on walking function and mobility in adults with peripheral artery disease.\n\nA total of 40 participants will be randomized to active lower-extremity heat therapy or sham therapy. Participants assigned to active therapy will complete daily 90-minute home treatment sessions using heated lower-extremity garments. Participants assigned to sham therapy will complete the same treatment schedule using a lower-temperature sham condition.\n\nThe primary outcome is the change in six-minute walk distance from baseline to 12 weeks. Secondary outcomes include changes in leg strength and fatigability, Short Physical Performance Battery score, blood pressure, and patient-reported quality of life.",[26,27],"PAD","PAD - Peripheral Arterial Disease","NOT_YET_RECRUITING","2026-06-12",{"date":31,"type":32},"2026-06-17","ACTUAL",{"date":34,"type":20},"2027-01-01",{"date":36,"type":20},"2029-06-30",{"name":38,"class":39},"Aquilo Sports, LLC","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100509708","the-thor-ide-study-100509708","NCT05916950","The THOR IDE Study","THOR","Inclusion Criteria:\n\n* Patient age is ≥18 years\n* Patient agrees to participate and to comply with the protocol by signing an IRB approved patient consent form\n* Patient is able to walk unassisted or with non-motorized assistive devices\n* Patient has PAD with documented Rutherford Class 2-4 of the target limb\n* Anticipated life expectancy \\>12 months, in the opinion of the investigator at the time of enrollment.\n\nAngiographic Inclusion Criteria:\n\n* Patient has de novo atherosclerotic disease of the native SFA and\u002For the popliteal arteries\n* Target lesion has ≥70% diameter stenosis by investigator via visual assessment\n* Target lesion length ≤150mm. Total treatment zone may not exceed 150mm, and may include one or more lesions.\n* Chronic total occlusion lesion length is \\\u003C100mm of the total ≤150mm target lesion\n* Minimum reference vessel diameter (RVD) 4.0mm by visual estimate\n* Target lesion crossed and intraluminal guidewire placement confirmed; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations\n* At least one patent tibial vessel (defined as \\\u003C50% stenosis) with runoff to the foot\n* Target lesion has moderate to severe calcification graded using the Peripheral Academic Research Consortium (PARC) criteria\n\nExclusion Criteria:\n\n* Patient has active infection requiring antibiotic therapy\n* Stenting planned within the target lesion\n* Known positive for COVID-19 within the last 2 weeks and actively symptomatic\n* Pregnant (positive pregnancy test) or currently breast feeding\n* Evidence of Acute Limb Ischemia in the target limb within 7 days prior to procedure\n* Cerebrovascular accident (CVA) \\\u003C60 days prior to procedure\n* Myocardial infarction \\\u003C60 days prior to procedure\n* History of unstable coronary artery disease or other uncontrollable comorbidity resulting in hospitalization within the last 60 days prior to baseline screening\n* Known contraindication to aspirin, or antiplatelet\u002Fanti-coagulant therapies required for procedure\u002Ffollow-up\n* Known allergy to contrast media that cannot adequately be premedicated prior to study procedure\n* History of Thrombophilia, Heparin-induced Thrombocytopenia (HIT), or Heparin-induced Thrombotic Thrombocytopenia Syndrome (HITTS)\n* Serum creatinine ≥2.5mg\u002FdL (unless dialysis-dependent) tested within 30 days prior to procedure\n* Planned lower limb major amputation (above the ankle)\n* Other surgical or endovascular procedure in the target limb that occurred within 14 days prior to index procedure or is planned on target limb for within 30 days following index procedure, with the exception of diagnostic angiography\n* Currently participating in any investigational device or drug clinical trial that, in the opinion of the investigator, will interfere with the conduct of the current study\n* The use of specialty balloons, re-entry or additional atherectomy devices is required for treatment of the target lesion.\n\nAngiographic Exclusion Criteria:\n\n* Subject has significant stenosis (\\>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated.\n* Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to the target site at the time of the index procedure.","18 Years",{"count":50,"type":20},155,[23],"The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD).\n\nThe main question\\[s\\] it aims to answer are:\n\n* Is the Thor system safe in treating these lesions\n* Does the Thor system work to treat these lesions\n\nParticipants will:\n\n* Receive treatment with the Thor system\n* Have follow-up visits at Discharge, 30 days, 6 months, and 12 months",[54,55,56,26],"Peripheral Artery Disease","Peripheral Artery Stenosis","Peripheral Artery Calcification","RECRUITING","2026-06-10",{"date":60,"type":32},"2026-06-11",{"date":62,"type":32},"2024-10-29",{"date":64,"type":20},"2027-12",{"name":66,"class":39},"Philips Clinical & Medical Affairs Global",29,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100602977","distrupt-stiffness-trial-100602977","NCT07130526","Distrupt Stiffness Trial","Trial to Investigate the Shockwave Intravascular Lithotripsy (IVL) on Vascular Compliance in Heavily Calcified Femoropopliteal Disease (PACSS 2-4)","Inclusion Criteria:\n\n* Peripheral artery disease\n* Severe Calcification PACCS 2,3 and 4\n* Target lesions in distal EIA, CFA, prox. SFA or PA\n* Clinical diagnosis of chronic, symptomatic lower limb ischemia as defined by Rutherford 2, 3, 4 and 5\n* Planed peripheral intervention TASC A-D\n* Subject must be between 18 and 85 years old\n* Willing to comply with the specified follow-up evaluation\n* Written informed consent prior to any study procedures\n\nExclusion Criteria:\n\n* Target lesions with no optimal visualization in ultrasound\n* Instent-Restenosis\n* Thrombolysis within 72 hours prior to the index procedure\n* Aneurysm formations in the femoral artery or popliteal artery\n* Concomitant hepatic insufficiency, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy\n* Unstable angina pectoris at the time of the enrolment\n* Recent myocardial infarction or stroke \\\u003C 30 days prior to the index procedure\n* Life expectancy less than 12 months\n* Septicemia at the time of enrolment\n* Known or suspected active infection at the time of the index procedure, excluding an infection of a lower extremity wound of the target limb\n* Known or suspected allergies or contraindications to aspirin, clopidogrel or heparin","85 Years",{"count":19,"type":20},[23],"Typical symptoms of PAD include exercise-induced pain in the legs (known as intermittent claudication), which can significantly limit pain-free walking. In more advanced stages, pain may also occur at rest. Additionally, the development of chronic, hard-to-heal wounds-especially on the feet and toes-is possible. These wound healing impairments are caused by the insufficient supply of oxygen and nutrients to the affected tissues.\n\nThe underlying cause of PAD is usually atherosclerosis, a pathological change in the vessel walls due to the accumulation of fats, calcium, and connective tissue. These deposits lead to stiffening and narrowing of the arteries, severely restricting blood flow. Major risk factors for the development of PAD include widespread chronic conditions such as diabetes mellitus, hyperlipidemia (elevated blood lipid levels, e.g., cholesterol), arterial hypertension (high blood pressure), obesity, and tobacco use.\n\nVarious therapeutic options are available for the treatment of PAD. In addition to conservative therapy (such as supervised exercise training, pharmacological blood thinning, and risk factor management), interventional, minimally invasive treatment using catheter-based techniques is frequently employed. In such procedures, a thin catheter is guided through the vascular system to the affected area of the leg artery. Depending on the type and extent of the arterial narrowing or calcification, one of the following techniques may be applied:\n\nBalloon angioplasty: Dilation of the vessel using an inflatable balloon. Lithoplasty: Application of shockwaves to break down calcifications in the arterial wall.",[27,26],[81,82,83],"pad","peripheral artery disease","intravascular lithotripsy","2025-08-15",{"date":86,"type":32},"2025-08-19",{"date":88,"type":32},"2025-07-01",{"date":90,"type":20},"2026-06-20",{"name":92,"class":93},"University Hospital, Essen","OTHER",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":40},"100423059","lncrnas-as-a-biomarker-to-assess-the-therapeutic-impact-of-oral-absorbent--probiotics-in-ckd-patients-with-pad-100423059","NCT04788914","lncRNAs as a Biomarker to Assess the Therapeutic Impact of Oral Absorbent ± Probiotics in CKD Patients With PAD","Circulating Long Noncoding RNA as a Biomarker to Assess the Therapeutic Impact of Oral Uremic Toxin Absorbent ± Probiotics in Chronic Kidney Disease Patients With Peripheral Arterial Disease","Inclusion Criteria:\n\nI: Patients\n\n1. Age \\> 20 years old on the day of screening.\n2. CKD patients with eGFR 15 \\\u003C eGFR \\\u003C 60 ml\u002Fmin\u002F1.73m2 in a stable status, creatinine elevated less than 0.3 mg\u002FdL in at least 30 days before enrollment.\n3. Symptomatic PAD with Rutherford Stage ≥ 2 and ABI \\\u003C 0.9 (or documented by CT-angio, vascular duplex, etc.).\n\nII: Controls\n\n1. Age \\> 20 years old on the day of screening.\n2. With eGFR \\> 60 ml\u002Fmin\u002F1.73m2\n3. No clinical PAD.\n\nExclusion Criteria:\n\n1. Baseline estimated glomerular filtration rates (eGFR) \\\u003C 15 ml\u002Fmin\u002F1.73m2 according to MDRD equation.\n2. Patients in severe malnutrition status, albumin less than 2.0 g\u002FdL\n3. Patients in severe anemia or active gastrointestinal bleeding with hemoglobulin \\\u003C 8 g\u002FdL.\n4. Peptic ulcer, esophageal varices, ileus or under fasting status\n5. Previous gastrointestinal operation.\n6. Chronic constipation, as defined with less than 3 bowel movements per week, straining, hard stools, incomplete evacuation and inability to pass stool. If usage of oral laxatives can achieve bowel movement, this patient will not be excluded.\n7. Patients with major hemorrhage, as defined with acute hemorrhage and requirement of blood transfusion during index admission.\n8. Patients with a biopsy proved or clinically diagnosed advanced liver cirrhosis, Child classification B or C.\n9. Solid organ or hematological transplantation recipients.\n10. Patients with oliguric kidney injury, as defined with less than 500 cc\u002Fday.\n11. Evidence of obstructive kidney injury or polycystic kidney disease.\n12. Antibiotics or probiotics treatment within the last 2 weeks before enrollment and during follow-up period.","20 Years",{"count":104,"type":20},180,[23],"Participants with chronic kidney disease (CKD) are at a higher risk of developing atherosclerotic peripheral artery disease (PAD). Retention of uremic toxins such as indoxyl sulfate (IS), p-cresyl sulfate (PCS) and trimethylamine N-oxide (TMAO) during CKD is detrimental to endothelial and vascular function and can predispose to the development and progression of PAD. Many of the uremic toxins originate from gut microbial metabolism. Removal of these uremic toxins by carbonaceous oral adsorbent is beneficial, slowing down the deterioration of renal function and delaying the need for dialysis in CKD patients. However, if carbonaceous oral adsorbent could also improve vascular function and clinical outcomes in CKD patients with established PAD, remains unknown.\n\nIn this proposal, the investigators aim to determine the therapeutic impact of a carbonaceous oral adsorbent made of activated bamboo charcoal (ABC) with\u002Fwithout probiotics on the endothelial\u002Fvascular function, CV outcome and mortality in CKD patients with PAD. In addition, the investigators hypothesize that circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota. The investigators also hypothesize that the administration of ABC could normalize the dysbiosis of gut microbiota, dysregulated circulating lncRNAs and metabolome that are linked to adverse CV\u002Flimb outcomes in CKD patients with PAD.\n\nThis will be a prospective, randomized, open-labeled, blinded end-point trial for 6 months, followed by integrated assessment of endothelial\u002Fvascular function, changes in conventional athero- and inflammation-relevant biomarkers, circulating long noncoding RNAs, metabolome, and gut microbiota at baseline, ends of the 3rd and 6th month, as well as clinical CV, renal and limb outcomes up to 3 years.",[108,26],"CKD",[110,111,112,108,26,113],"Bamboo charcoal","LncRNA","gut microbiota","Probiotics","2025-07-16",{"date":116,"type":32},"2025-07-17",{"date":118,"type":32},"2020-04-21",{"date":120,"type":20},"2025-07-31",{"name":122,"class":93},"National Taiwan University Hospital",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":130,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":40},"100556751","effect-of-breather-in-copd-patients-with-intermittent-claudication-100556751","NCT06529185","Effect of Breather in COPD Patients With Intermittent Claudication","Effect of Breather on Ventilatory and Vascular Function in Chronic Obstructive Pulmonary Disease Patients With Intermittent Claudication.","Inclusion Criteria:\n\n* sixty male patients with diagnosed with grade I and grade II COPD their ages ranged between 55-60years\n* All patients will be clinically and medically stable when attending the study.\n* Body mass index (BMI) is 18.5 to 24.9 kg\u002Fm2.\n* History of unilateral exertional leg pain,\n* Ambulation during a graded treadmill test limited by leg pain consistent with intermittent claudication (stage II of the fontaine classification of pad),\n* And an ankle-brachial index (ABI) of 0.90 or lower at rest or 0.73 or lower after exercise.\n\nExclusion Criteria:\n\n* cardiovascular insufficiency,\n* Recent myocardial infarction,\n* heart failure,\n* arrhythmia,\n* DVT,\n* Intracranial hypertension,\n* Pneumonia,\n* kidney failure,\n* fractures,\n* uncooperative patients,\n* cognitive impairment preventing a patient from participation in exercises.","MALE","60 Years",{"count":133,"type":20},60,[23],"The aim of this study To show the effect of breather on ventilatory and vascular function in COPD patient with intermittent claudication.",[137,26],"COPD","2024-12-30",{"date":140,"type":32},"2024-12-31",{"date":142,"type":32},"2024-07-30",{"date":144,"type":20},"2025-02",{"name":146,"class":93},"Cairo University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":164,"leadSponsor":166,"locationsCount":40},"100465800","endovascular-denervation-for-the-treatment-of-patients-with-peripheral-arterial-disease-100465800","NCT05345431","Endovascular Denervation for the Treatment of Patients With Peripheral Arterial Disease","EDPAD","Inclusion Criteria:\n\n1. eligible subjects aged 18-75 years,\n2. clinically confirmed PAD patients in Rutherford category II-VI.\n\nExclusion Criteria:\n\n1. thrombolytic therapy performed within 30 days,\n2. patients who had undergone vascular bypass surgery before this study,\n3. allergy or contraindication of antiplatelet drugs, anticoagulants, thrombolytic drugs and contrast agents,\n4. patients with obvious bleeding tendency, coagulation dysfunction, hypercoagulability and blood system diseases,\n5. serious liver and kidney diseases,\n6. history of hemorrhagic stroke within the last 1 month or ischemic stroke or transient ischemic attack within 2 weeks,\n7. pacemaker implants,\n8. patients who are pregnant, breast-feeding or planning pregnancy,\n9. expected survival \\\u003C 24 months.","75 Years",{"count":156,"type":20},54,[23],"Sympathetic overactivity partly promotes the development of peripheral artery disease which mainly leads to ischemia of the lower limbs. Endovascular arterial denervation (ED) is a minimally invasive technique which could deliver Radiofrequency energy by a multi-electrode catheter to the Lower limb artery to restore Sympathetic activity. The purpose of this study is to evaluate the effects of multi-electrode radiofrequency ablation system on lower limb ischemia with PAD.",[26],"2022-04-20",{"date":162,"type":32},"2022-04-25",{"date":162,"type":20},{"date":165,"type":20},"2026-06-30",{"name":167,"class":93},"Zhongda Hospital"]